In people with primary progressive multiple sclerosis (MS), a new study has found no difference in the amount of time before ...

Oditrasertib, which blocks the inflammatory RIPK1 protein, earlier this year also failed a Phase II trial in amyotrophic ...

The FDA has approved a new injectable form of the multiple sclerosis drug ocrelizumab for use in adults with relapsing and progressive forms of the disease. Multiple sclerosis occurs when the body ...

Furthest ahead in the pipeline is tolebrutinib, developed by Paris-based Sanofi to potentially treat SPMS, PPMS and relapsing forms of MS. The investigational agent is an oral central nervous system ...

Some cancers occurred more frequently in people with multiple sclerosis (MS) than in others, a retrospective study in France ...

The medicine, called ocrelizumab, is normally given as an infusion through a vein - a process that can take up to four hours in hospital. The new way to give the drug will help free up patients ...

The report explains that Pharmac’s current funding model is a cost utility analysis (CUA), which is a subset of cost effectiveness analysis. In this, Pharmac weighs up the direct healthcare costs and ...

High-efficacy therapy was defined as ocrelizumab (Ocrevus), rituximab (Rituxan), or natalizumab (Tysabri). At ages 23-27, those who had earlier treatment had less disability, said Sifat Sharmin ...

Chair of the Meningitis Foundation, Gerard Rushton says he fully supports MSNZ and its call for Pharmac to adopt a new funding evaluation model that considers more than just the direct healthcare ...

The cochlea houses the cell bodies of the cochlear nerve within a region called the spiral ganglion. Nerve cells (neurons) in ...

However, as most data is registry-based and previous trials did not directly compare aHSCT with the most efficacious DMTs, Alemtuzumab, Ocrelizumab, Cladribine and Ofatumumab, questions remain over ...

About 10 to 15% of people with the disease have this type of MS. The study looked at rituximab and ocrelizumab, anti-CD20 infusion therapies that target a protein called CD20 found on some white ...